{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T12:06:38Z","timestamp":1791633998067,"version":"4.3.4"},"reference-count":54,"publisher":"Institute of Physiology of the Czech Academy of Sciences","issue":"3\/2025","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Physiol Res"],"abstract":"<jats:p>Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease associated with increased cardiovascular morbidity and mortality. Myocardial fibrosis, a key pathological consequence of prolonged inflammation, contributes to diastolic dysfunction and the development of heart failure with preserved ejection fraction (HFpEF) in RA patients. Understanding its pathophysiology, early detection, and potential therapeutic strategies is crucial for improving patient outcomes. In this study we explore the underlying mechanisms of myocardial fibrosis in RA, focusing on immune-mediated pathways, oxidative stress, and extracellular matrix dysregulation, with concise look at the impact of immunosuppressive therapy on cardiac remodeling and role of speckle-tracking echocardiography (STE) in detecting subclinical myocardial fibrosis, emphasizing global longitudinal strain (GLS) as a promising surrogate marker.<\/jats:p>","DOI":"10.33549\/physiolres.935575","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T08:40:44Z","timestamp":1753260044000},"page":"347-358","source":"Crossref","is-referenced-by-count":5,"title":["Myocardial Fibrosis, The Silent Instigator of Diastolic Dysfunction in Patients With Rheumatoid Arthritis"],"prefix":"10.33549","author":[{"given":"M","family":"Jalali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"\u0160tevl\u00edk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Jalali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Ga\u017eov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Kyselovi\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z","family":"Killinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Payer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"19169","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1.\tChen J, Norling LV, Cooper D. Cardiac Dysfunction in Rheumatoid Arthritis: The Role of Inflammation. Cells 2021;10:881. https:\/\/doi.org\/10.3390\/cells10040881","DOI":"10.3390\/cells10040881"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2.\t\u00d6zkan U, Kakilli N, G\u00fcrdo\u011fan M, Ta\u015ftekin N, Birtane M. Rheumatoid arthritis and cardiovascular comorbidities. Explor Musculoskeletal Dis 2023;1:264-288. https:\/\/doi.org\/10.37349\/emd.2023.00028","DOI":"10.37349\/emd.2023.00028"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3.\tDavis JM 3rd, Lin G, Oh JK, Crowson CS, Achenbach SJ, Therneau TM, Matteson EL, et al. Five-year changes in cardiac structure and function in patients with rheumatoid arthritis compared with the general population. Int J Cardiol 2017;240:379-385. https:\/\/doi.org\/10.1016\/j.ijcard.2017.03.108","DOI":"10.1016\/j.ijcard.2017.03.108"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4.\tAlexandre A, S\u00e1-Couto D, Brand\u00e3o M, Cabral S, Fonseca T, Costa RQ, Marinho A, Vasconcelos C, et al. Subclinical left ventricular dysfunction in rheumatoid arthritis: findings from the prospective Porto-RA cohort. Clin Res Cardiol 2024. https:\/\/doi.org\/10.1007\/s00392-024-02548-6","DOI":"10.1007\/s00392-024-02548-6"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5.\tSchau T, Gottwald M, Arbach O, Seifert M, Sch\u00f6pp M, Neu\u00df M, Butter C, Z\u00e4nker M. Increased Prevalence of Diastolic Heart Failure in Patients with Rheumatoid Arthritis Correlates with Active Disease, but Not with Treatment Type. J Rheumatol 2015;42:2029-2037. https:\/\/doi.org\/10.3899\/jrheum.141647","DOI":"10.3899\/jrheum.141647"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6.\tPaulus WJ, Zile MR. From Systemic Inflammation to Myocardial Fibrosis. Circ Res 2021;128:1451-1467. https:\/\/doi.org\/10.1161\/CIRCRESAHA.121.318159","DOI":"10.1161\/CIRCRESAHA.121.318159"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7.\tKune\u0161 J, Hojn\u00e1 S, Mr\u00e1zikov\u00e1 L, Montezano A, Touyz RM, Malet\u00ednsk\u00e1 L. Obesity, Cardiovascular and Neurodegenerative Diseases: Potential Common Mechanisms. Physiol Res 2023;72(Suppl 2):S73-S90. https:\/\/doi.org\/10.33549\/physiolres.935109","DOI":"10.33549\/physiolres.935109"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8.\tPark E, Griffin J, Bathon JM. Myocardial Dysfunction and Heart Failure in Rheumatoid Arthritis. Arthritis Rheumatol 2022;74:184-199. https:\/\/doi.org\/10.1002\/art.41979","DOI":"10.1002\/art.41979"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9.\tBorsky P, Fiala Z, Andrys C, Beranek M, Hamakova K, Kremlacek J, Malkova A, et al. C-reactive protein, chemerin, fetuin-A and osteopontin as predictors of cardiovascular risks in persons with psoriasis vulgaris. Physiol Res 2021;70:383-391. https:\/\/doi.org\/10.33549\/physiolres.934654","DOI":"10.33549\/physiolres.934654"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10.\tGrillet B, Pereira RVS, Van Damme J, Abu El-Asrar A, Proost P, Opdenakker G. Matrix metalloproteinases in arthritis: towards precision medicine. Nat Rev Rheumatol 2023;19:363-377. https:\/\/doi.org\/10.1038\/s41584-023-00966-w","DOI":"10.1038\/s41584-023-00966-w"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11.\tKotake S, Yago T, Kobashigawa T, Nanke Y. The Plasticity of Th17 Cells in the Pathogenesis of Rheumatoid Arthritis. J Clin Med 2017;6:67. https:\/\/doi.org\/10.3390\/jcm6070067","DOI":"10.3390\/jcm6070067"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12.\tMaggi L, Mazzoni A, Cimaz R, Liotta F, Annunziato F, Cosmi L. Th17 and Th1 Lymphocytes in Oligoarticular Juvenile Idiopathic Arthritis. Front Immunol 2019;10:450. https:\/\/doi.org\/10.3389\/fimmu.2019.00450","DOI":"10.3389\/fimmu.2019.00450"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13.\tSilverman GJ, Carson DA. Roles of B cells in rheumatoid arthritis. Arthritis Res Ther 2003;5(Suppl 4):S1-S6. https:\/\/doi.org\/10.1186\/ar1010","DOI":"10.1186\/ar1010"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14.\tda Fonseca LJS, Nunes-Souza V, Goulart MOF, Rabelo LA. Oxidative Stress in Rheumatoid Arthritis: What the Future Might Hold regarding Novel Biomarkers and Add-On Therapies. Oxid Med Cell Longev 2019;2019:7536805. https:\/\/doi.org\/10.1155\/2019\/7536805","DOI":"10.1155\/2019\/7536805"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15.\tLuo P, Xu W, Ye D, Chen W, Ying J, Liu B, Li J, et al. Metabolic Syndrome Is Associated With an Increased Risk of Rheumatoid Arthritis: A Prospective Cohort Study Including 369,065 Participants. J Rheumatol 2024;51:360-367. https:\/\/doi.org\/10.3899\/jrheum.2023-0349","DOI":"10.3899\/jrheum.2023-0349"},{"key":"ref15","unstructured":"16.\tFirestein GS. Pathogenesis of rheumatoid arthritis: the intersection of genetics and epigenetics. Trans Am Clin Climatol Assoc 2018;129:171-182."},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17.\tNguyen MN, Kiriazis H, Gao XM, Du XJ. Cardiac Fibrosis and Arrhythmogenesis. Compr Physiol 2017;7:1009-1049. https:\/\/doi.org\/10.1002\/j.2040-4603.2017.tb00771.x","DOI":"10.1002\/j.2040-4603.2017.tb00771.x"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18.\tZeller CB, Appenzeller S. Cardiovascular disease in systemic lupus erythematosus: the role of traditional and lupus related risk factors. Curr Cardiol Rev 2008;4:116-122. https:\/\/doi.org\/10.2174\/157340308784245775","DOI":"10.2174\/157340308784245775"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19.\tLazzerini PE, Laghi-Pasini F, Boutjdir M, Capecchi PL. Cardioimmunology of arrhythmias: the role of autoimmune and inflammatory cardiac channelopathies. Nat Rev Immunol 2019;19:63-64. https:\/\/doi.org\/10.1038\/s41577-018-0098-z","DOI":"10.1038\/s41577-018-0098-z"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"20.\tGulati A, Jabbour A, Ismail TF, Guha K, Khwaja J, Raza S, Morarji K, et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA 2013;309:896-908. https:\/\/doi.org\/10.1001\/jama.2013.1363","DOI":"10.1001\/jama.2013.1363"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21.\tDraghi A, Borch TH, Radic HD, Chamberlain CA, Gokuldass A, Svane IM, Donia M. Differential effects of corticosteroids and anti-TNF on tumor-specific immune responses: implications for the management of irAEs. Int J Cancer 2019;145:1408-1413. https:\/\/doi.org\/10.1002\/ijc.32080","DOI":"10.1002\/ijc.32080"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22.\tSzappanos \u00c1, Hajas \u00c1, Harty\u00e1nszky I Jr, K\u00e1d\u00e1r K, Kuthi L, Harty\u00e1nszky I, Merkely B, Nagy AI. Severe cardiovascular manifestation of ASIA syndrome triggered by silicone breast implants. Rheumatology (Oxford) 2025;64:1550-1552. https:\/\/doi.org\/10.1093\/rheumatology\/keae564","DOI":"10.1093\/rheumatology\/keae564"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23.\tLazou A, Ikonomidis I, Bartekova M, Benedek T, Makavos G, Palioura D, Cabrera Fuentes H, Andreadou I. Chronic inflammatory diseases, myocardial function and cardioprotection. Br J Pharmacol 2020;177:5357-5374. https:\/\/doi.org\/10.1111\/bph.14975","DOI":"10.1111\/bph.14975"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24.\tPadjen I, Crnogaj MR, Ani\u0107 B. Conventional disease-modifying agents in rheumatoid arthritis - a review of their current use and role in treatment algorithms. Reumatologia 2020;58:390-400. https:\/\/doi.org\/10.5114\/reum.2020.101400","DOI":"10.5114\/reum.2020.101400"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25.\tRoubille C, Coffy A, Rincheval N, Dougados M, Flipo RM, Daur\u00e8s JP, Combe, B. Ten-year analysis of the risk of severe outcomes related to low-dose glucocorticoids in early rheumatoid arthritis. Rheumatology (Oxford) 20212;60:3738-3746. https:\/\/doi.org\/10.1093\/rheumatology\/keaa850","DOI":"10.1093\/rheumatology\/keaa850"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26.\tBarnabe C, Martin B-J, Ghali WA. Systematic review and meta-analysis: Anti-tumor necrosis factor \u03b1 therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2011;63:522-529. https:\/\/doi.org\/10.1002\/acr.20371","DOI":"10.1002\/acr.20371"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27.\tSlez\u00e1k J, Kura B, Frimmel K, Z\u00e1le\u0161\u00e1k M, Ravingerov\u00e1 T, Viczenczov\u00e1 C, Okruhlicov\u00e1 \u013d, Tribulov\u00e1 N. Preventive and therapeutic application of molecular hydrogen in situations with excessive production of free radicals. Physiol Res 2016;65(Suppl 1):S11-S28. https:\/\/doi.org\/10.33549\/physiolres.933414","DOI":"10.33549\/physiolres.933414"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"28.\tRoubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2015;74:480-489. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206624","DOI":"10.1136\/annrheumdis-2014-206624"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"29.\tSetoguchi S, Schneeweiss S, Avorn J, Katz JN, Weinblatt ME, Levin R, Solomon DH. Tumor necrosis factor-\u03b1 antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am Heart J 2008;156:336-341. https:\/\/doi.org\/10.1016\/j.ahj.2008.02.025","DOI":"10.1016\/j.ahj.2008.02.025"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"30.\tColetta AP, Clark AL, Banarjee P, Cleland JGF. Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH. Eur J Heart Fail 2002;4:559-561. https:\/\/doi.org\/10.1016\/S1388-9842(02)00121-6","DOI":"10.1016\/s1388-9842(02)00121-6"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"31.\tBozkurt B, Torre-Amione G, Warren MS, Whitmore J, Soran OZ, Feldman AM, Mann DL. Results of Targeted Anti-Tumor Necrosis Factor Therapy With Etanercept (ENBREL) in Patients With Advanced Heart Failure. Circulation 2001;103:1044-1047. https:\/\/doi.org\/10.1161\/01.CIR.103.8.1044","DOI":"10.1161\/01.cir.103.8.1044"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"32.\tChung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107:3133-3140. https:\/\/doi.org\/10.1161\/01.CIR.0000077913.60364.D2","DOI":"10.1161\/01.cir.0000077913.60364.d2"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"33.\tSingh S, Fumery M, Singh AG, Singh N, Prokop LJ, Dulai PS, Sandborn WJ, Curtis JR. Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken) 2020;72:561-576. https:\/\/doi.org\/10.1002\/acr.23875","DOI":"10.1002\/acr.23875"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"34.\tFeng R, Liu H, Chen Y. Baricitinib represses the myocardial fibrosis via blocking JAK\/STAT and TGF-\u03b21 pathways in vivo and in vitro. BMC Cardiovasc Disord 2025;25:65. https:\/\/doi.org\/10.1186\/s12872-025-04517-x","DOI":"10.1186\/s12872-025-04517-x"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"35.\tHasni SA, Gupta S, Davis M, Poncio E, Temesgen-Oyelakin Y, Carlucci PM, Wang X, et al. Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nat Commun 2021;12:3391. https:\/\/doi.org\/10.1038\/s41467-021-23361-z","DOI":"10.1038\/s41467-021-23361-z"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"36.\tBuch MH, Mallat Z, Dweck MR, Tarkin JM, O'Regan DP, Ferreira V, Youngstein T, Plein S. Current understanding and management of cardiovascular involvement in rheumatic immune-mediated inflammatory diseases. Nat Rev Rheumatol 2024;20:614-634. https:\/\/doi.org\/10.1038\/s41584-024-01149-x","DOI":"10.1038\/s41584-024-01149-x"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"37.\tFardet L, Petersen I, Nazareth I. Risk of cardiovascular events in people prescribed glucocorticoids with iatrogenic Cushing's syndrome: cohort study. BMJ 2012;345:e4928. https:\/\/doi.org\/10.1136\/bmj.e4928","DOI":"10.1136\/bmj.e4928"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"38.\tRidker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E, Mam V, et al. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. N Engl J Med 2019;380:752-762. https:\/\/doi.org\/10.1056\/NEJMoa1809798","DOI":"10.1056\/nejmoa1809798"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"39.\tSitia S, Tomasoni L, Turiel M. Speckle tracking echocardiography: A new approach to myocardial function. World J Cardiol 2010;2:1-5. https:\/\/doi.org\/10.4330\/wjc.v2.i1.1","DOI":"10.4330\/wjc.v2.i1.1"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"40.\tNeradilova C, Gregorovicova M, Kovanda J, Kvasilova A, Melenovsky V, Nanka O, Sedmera D. \"Form follows function\": the developmental morphology of the cardiac atria. Physiol Res 2024;73(Suppl 3):S697-S714. https:\/\/doi.org\/10.33549\/physiolres.935503","DOI":"10.33549\/physiolres.935503"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"41.\tAbou R, van der Bijl P, Bax JJ, Delgado V. Global longitudinal strain: clinical use and prognostic implications in contemporary practice. Heart 2020;106:1438-1444. https:\/\/doi.org\/10.1136\/heartjnl-2019-316215","DOI":"10.1136\/heartjnl-2019-316215"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"42.\tChadalavada S, Rauseo E, Sanghvi M, Lee AM, Amir-Khalili A, Chirvasa M, Banik S, et al. Diabetes worsens the adverse association between myocardial diffuse fibrosis and left ventricular strain. Eur Heart J 2024;45(Suppl 1):ehae666.252. https:\/\/doi.org\/10.1093\/eurheartj\/ehae666.252","DOI":"10.1093\/eurheartj\/ehae666.252"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"43.\tWitt UE, M\u00fcller ML, Beyer RE, Wieditz J, Salem S, Hashemi D, Chen W, et al. A simplified approach to discriminate between healthy subjects and patients with heart failure using cardiac magnetic resonance myocardial deformation imaging. Eur Heart J Imaging Methods Pract 2024;2:qyae093. https:\/\/doi.org\/10.1093\/ehjimp\/qyae093","DOI":"10.1093\/ehjimp\/qyae093"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"44.\tAbdelrahman Elkassas LS, Raief Mosaad BM, Ibrahim AS. Advanced Myocardial Characterization in Hypertrophic Cardiomyopathy: Feasibility of CMR-based Feature Tracking Strain Analysis. QJM-Int J Med 2024;117(Suppl 1):hcae070.568. https:\/\/doi.org\/10.1093\/qjmed\/hcae070.568","DOI":"10.1093\/qjmed\/hcae070.568"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"45.\tHu X, Bao Y, Zhu Y, Zheng K, Zhang J, Zhou W, Deng Y, Liu Y. Predicting Left Ventricular Myocardial Fibrosis in Patients with Hypertrophic Cardiomyopathy by Speckle Tracking Automated Functional Imaging. Ultrasound Med Biol 2023;49:1309-1317. https:\/\/doi.org\/10.1016\/j.ultrasmedbio.2023.01.020","DOI":"10.1016\/j.ultrasmedbio.2023.01.020"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"46.\tLi Y, Liu J, Cao Y, Han X, Shao G, Zhou X, Gu J, et al. Predictive values of multiple non-invasive markers for myocardial fibrosis in hypertrophic cardiomyopathy patients with preserved ejection fraction. Sci Rep 2021;11:4297. https:\/\/doi.org\/10.1038\/s41598-021-83678-z","DOI":"10.1038\/s41598-021-83678-z"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"47.\tReiber JHC. Global longitudinal strain (GLS). Int J Cardiovasc Imaging 2022;38:269-270. https:\/\/doi.org\/10.1007\/s10554-022-02556-5","DOI":"10.1007\/s10554-022-02556-5"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"48.\tHarper AR, Patel HC, Lyon AR. Heart failure with preserved ejection fraction. Clin Med (Lond) 2018;18(Suppl 2):S24-S29. https:\/\/doi.org\/10.7861\/clinmedicine.18-2-s24","DOI":"10.7861\/clinmedicine.18-2-s24"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"49.\tRegitz-Zagrosek V, Kararigas G. Mechanistic Pathways of Sex Differences in Cardiovascular Disease. Physiol Rev 2017;97:1-37. https:\/\/doi.org\/10.1152\/physrev.00021.2015","DOI":"10.1152\/physrev.00021.2015"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"50.\tMetsios GS, Stavropoulos-Kalinoglou A, Kitas GD. The role of exercise in the management of rheumatoid arthritis. Expert Rev Clin Immunol 2015;11:1121-1130. https:\/\/doi.org\/10.1586\/1744666X.2015.1067606","DOI":"10.1586\/1744666x.2015.1067606"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"51.\tMetsios GS, Stavropoulos-Kalinoglou A, Veldhuijzen van Zanten JJ, Nightingale P, Sandoo A, Dimitroulas T, Kitas GD, Koutedakis Y. Individualised exercise improves endothelial function in patients with rheumatoid arthritis. Ann Rheum Dis 2014;73:748-751. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203291","DOI":"10.1136\/annrheumdis-2013-203291"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"52.\tCooney JK, Law RJ, Matschke V, Lemmey AB, Moore JP, Ahmad Y, Jones JG, et al. Benefits of exercise in rheumatoid arthritis. J Aging Res 2011;2011:681640. https:\/\/doi.org\/10.4061\/2011\/681640","DOI":"10.4061\/2011\/681640"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"53.\tSk\u00f6ldstam L, Hagfors L, Johansson G. An experimental study of a Mediterranean diet intervention for patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:208-214. https:\/\/doi.org\/10.1136\/ard.62.3.208","DOI":"10.1136\/ard.62.3.208"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"54.\tMontoya T, S\u00e1nchez-Hidalgo M, Castej\u00f3n ML, Rosillo M, Gonz\u00e1lez-Benjumea A, Alarc\u00f3n-de-la-Lastra C. Dietary Oleocanthal Supplementation Prevents Inflammation and Oxidative Stress in Collagen-Induced Arthritis in Mice. Antioxidants (Basel) 2021;10:650. https:\/\/doi.org\/10.3390\/antiox10050650","DOI":"10.3390\/antiox10050650"}],"container-title":["Physiological Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T08:40:48Z","timestamp":1753260048000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.biomed.cas.cz\/physiolres\/pdf\/2025\/74_347.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":54,"journal-issue":{"issue":"3\/2025","published-online":{"date-parts":[[2025,7,21]]}},"URL":"https:\/\/doi.org\/10.33549\/physiolres.935575","relation":{},"ISSN":["1802-9973","0862-8408"],"issn-type":[{"value":"1802-9973","type":"electronic"},{"value":"0862-8408","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,21]]}}}